Supplementary Tables 1 and 2 and Supplementary Figures 1 through 5 from The Dual MEK/FLT3 Inhibitor E6201 Exerts Cytotoxic Activity against Acute Myeloid Leukemia Cells Harboring Resistance-Conferring FLT3 Mutations

<p>Supplementary Table 1. Gene alterations and cytogenic information of AML patients. Supplementary Table 2. Comparison of IC50s of E6201 and AC220 in murine ITD mutant and TKDs mutant cell lines. Fig. S1. Molecular structures of drugs used in this study. Fig. S2. Normal bone marrow samples (three cases) were treated with indicated concentration of E6201 for 72 hours and apoptosis induction was measured by stained with annexin V-Fluo and counting annexin V positivity using flow cytometry. Fig. S3. Body weight of mice was measured at Day 4, in which the mice started E6201 (n = 11) or vehicle (n = 10) treatment, and Day 18 after MOLM13-Luci-GFP cells injection. Fig. S4. Baf3-ITD+691 cells were treated with E6201 for 1 hour and protein profiling of correlated signaling pathways was determined using immunoblotting. Fig. S5. OCI/AML3 and MOLM13 p53 knock down (KD) cells and their respective controls were treated with E6201 for E6201 for 72 hour and apoptosis induction were assessed as the percentage of annexin V-positive cells by flow cytometry.</p>